Form D · Biotechnology
Oricula Therapeutics LLC
Seattle, WA · CIK 0001590934
Offering snapshot reported Apr 22, 2020 · SEC filing
- Reported sold
- Yet to sell Offering amount: $500K
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 22, 2020 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Dec 22, 2017 | Initial | $30,000 | No comparison | 1 | SEC filing |
| May 15, 2017 | Initial | $25,000 | No comparison | 1 | SEC filing |
| Jan 21, 2015 | Initial | $45,000 | No comparison | 1 | SEC filing |
| Nov 4, 2013 | Initial | $75,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-365611
Source: Form D, filed Apr 22, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Malcolm Gleser | Director, Executive, Promoter |
| Vince Groppi | Director, Promoter |
| Ed Rubel | Director, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
474 39 Th Avenue East
Seattle, WA, 98112
Seattle, WA, 98112